Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply

Documenti analoghi

• Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
  di: Yash Hegde, et al.
  Pubblicazione: (2026)
• Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
  di: Anupam Kumar Singh, et al.
  Pubblicazione: (2025)
• Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
  di: Cristina Rubín de Célix, et al.
  Pubblicazione: (2025)
• Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
  di: Luisa Bertin, et al.
  Pubblicazione: (2026)
• Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
  di: Isabel Carbery, et al.
  Pubblicazione: (2024)